Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Very Positive)

Rhea-AI Summary

Oculis (OCS) reported notifications of transactions by persons discharging managerial responsibilities. These relate to vesting and settlement of RSUs previously granted to directors, annual equity incentive awards to directors, and a one-time equity grant to a new director upon his election to the board.

AI-generated analysis. How Rhea-AI works. Not financial advice.

News Market Reaction – OCS

-7.33%

-7.33% News Effect

On the day this news was published, OCS declined 7.33%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

What This Means

The stock moved -7.3% in the session following this news. A negative reaction despite the routine na...

Analysis

The stock moved -7.3% in the session following this news. A negative reaction despite the routine nature of director RSU vesting and equity awards would fit a pattern where some positive or neutral updates coincided with selling, such as the -6.86% move after Q1 2026 results. With shares still above the 200-day MA of 22.69, pullbacks have previously occurred within a longer-term uptrend. Prior dilutive financings and warrant-related overhangs could also influence how the market interprets governance disclosures.

Key Figures

Registered resale shares: 494,259 shares Currently exercisable warrant: 59,310 shares Potential cash proceeds: $6,877,246.59 +5 more

8 metrics

Registered resale shares 494,259 shares Form F-3 resale registration

Currently exercisable warrant 59,310 shares Portion of warrant currently exercisable

Potential cash proceeds $6,877,246.59 If warrant fully exercised for maximum shares

Financing shares 5,432,098 shares Equity financings announced October 31, 2025

Gross proceeds $110.0 million Equity financings announced October 31, 2025

Offering price $20.25 per share Underwritten and registered direct offerings

Shares outstanding pre-offer 52,374,811 shares As of September 30, 2025

Shares outstanding post-offer 57,806,909 shares Expected after offerings and direct sale

Historical Context

4 past events · Latest: May 11 (Positive)

Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
May 11	Q1 earnings update	Positive	-6.9%	Reported Q1 results, strong cash runway, and late-stage pipeline timelines.
May 07	Regulatory SPA news	Positive	+5.1%	FDA Special Protocol Assessment for PIONEER-1 Phase 3 Privosegtor trial.
May 05	Clinical conference data	Positive	-1.8%	Presented DME AWARE Delphi findings and reiterated June 2026 DIAMOND data.
Apr 21	AGM invitation	Neutral	+0.0%	Published notice and logistics for the 2026 Annual General Meeting.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has triggered mixed reactions: some positive clinical and regulatory milestones saw selling pressure, while others aligned with moderate gains.

Recent Company History

Over the past month, Oculis reported Q1 2026 results with cash of $277.6 million and runway into 2H 2029, yet shares fell -6.86%. A Special Protocol Assessment for the Phase 3 PIONEER-1 trial in optic neuritis led to a 5.1% gain, while ARVO-related DME AWARE and DIAMOND updates saw a modest -1.8% move. The AGM invitation had little impact. Today’s RSU vesting and director equity awards fit into routine governance activity against this backdrop of clinically focused catalysts.

Regulatory & Risk Context

Active S-3 Shelf · Short Interest: 1.22%

Shelf Active

Short Interest

1.22% of shares outstanding

as of 2026-05-29 Days to cover: 1

Active S-3 Shelf Registration 2025-11-10

An effective Form F-3 dated November 10, 2025 registers the resale of up to 494,259 ordinary shares issuable from a warrant. Oculis is not selling securities under this prospectus and receives no proceeds from resales, but could receive up to $6,877,246.59 in cash if the warrant is fully exercised at strike prices of $12.17 and $18.64 per share.

Key Terms

rsus

1 terms

rsus financial

"the vesting and settlement of RSUs previously granted to directors of the Company"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

05/15/2026 - 04:05 PM

ZUG, Switzerland, May 15, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company, the annual equity incentive awards granted to directors of the Company, and the one-time equity incentive award granted to a new director upon his election to the board of directors of the Company.

Attachments

FAQ

What transactions did Oculis (OCS) report on May 15, 2026?

Oculis reported notifications of transactions involving directors’ restricted stock units and equity awards. According to Oculis, these cover RSU vesting and settlement, annual director equity incentives, and a one-time equity award for a newly elected board member.

Which Oculis (OCS) directors had RSU vesting transactions on May 13, 2026?

According to Oculis, RSU vesting notifications were filed for directors Anthony Rosenberg, Christina Ackermann, Arshad Khanani and Robert Warner. These transactions reflect the vesting and settlement of previously granted restricted stock units to these board members.

What equity incentive awards did Oculis (OCS) directors receive in 2026?

Oculis filed notifications for annual equity incentive awards granted to several directors in 2026. According to Oculis, these annual grants form part of the board’s compensation structure and are documented in individual manager transaction notifications for each named director.

Did Oculis (OCS) grant equity to a new director in 2026?

Yes. Oculis reported a one-time equity incentive award for new director G. Perry. According to Oculis, this award was granted upon his election to the board and is disclosed in a dedicated manager transaction notification.

Why does Oculis (OCS) publish notifications of managers’ transactions?

Oculis publishes managers’ transaction notifications to disclose equity dealings by directors and similar insiders. According to Oculis, the reported 2026 items include RSU vesting, annual equity awards and a new director grant, supporting transparency around board-related share incentives.